Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4694568 | 0.82 | ADORA2A (0.37) | CNR2PLAUERN1ADORA3ADORA2A | |
| SCHEMBL6334980 | 0.78 | ADORA2A (0.35) | POLBCNR2ERN1HDAC2ADORA3 | |
| SCHEMBL4477931 | 0.69 | CSNK2A1 (0.34) | — | |
| SCHEMBL4478147 | 0.69 | CYP1A2 (0.31) | — | |
| SCHEMBL4463886 | 0.69 | ERN1 (0.33) | ERN1 | |
| SCHEMBL6336378 | 0.69 | ERN1 (0.30) | ERN1ADORA2B | |
| SCHEMBL15650192 | 0.68 | DHODH (0.43) | ALOX5POLBCNR2PLAUERN1 | |
| SCHEMBL5247315 | 0.68 | ADORA2A (0.37) | CNR2ERN1ADORA3ADORA2AADORA2B | |
| SCHEMBL17592087 | 0.66 | ERN1 (0.33) | ERN1 | |
| SCHEMBL4473652 | 0.66 | CYP1A1 (0.35) | PLAUERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533949-B2 | Processes for the preparation of 3-alkyl indoles | APOTEX PHARMACHEM INC. (CA) | 2017-01-03 | — | — | US | disclosed |
| US-20150252000-A1 | PROCESSES FOR THE PREPARATION OF 3-ALKYL INDOLES | APOTEX INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| WO-2014040164-A1 | PROCESSES FOR THE PREPARATION OF 3-ALKYL INDOLES | APOTEX PHARMACHEM INC. (CA) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252000-A1 | PROCESSES FOR THE PREPARATION OF 3-ALKYL INDOLES | GALR3, GALR2, GALR1 | ALOX5 1240/4885POLB 4235/4885CNR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.